Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Linagliptin”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00328172
What this trial is testing

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 302
Early research (Phase 1)Study completedNCT02183337
What this trial is testing

Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 20
Post-approval studies (Phase 4)UnknownNCT02280174
What this trial is testing

Effect of Linagliptin on TRL Metabolism

Who this might be right for
Type 2 Diabetes
Ministry of Public Health, Argentina 20
Post-approval studies (Phase 4)Study completedNCT01438814
What this trial is testing

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 689
Not applicableStudy completedNCT01707147
What this trial is testing

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 3,219
Post-approval studies (Phase 4)UnknownNCT05200793
What this trial is testing

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Who this might be right for
Polycystic Ovary Syndrome (PCOS)
Alexandria University 75
Large-scale testing (Phase 3)Ended earlyNCT02077309
What this trial is testing

Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus Type 2 (T2DM)Vascular InflammationPlaque Morphology
RWTH Aachen University 4
Early research (Phase 1)Study completedNCT02183480
What this trial is testing

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 12
Post-approval studies (Phase 4)Study completedNCT02401880
What this trial is testing

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Who this might be right for
Type 2 Diabetes Mellitus
Profil Institut für Stoffwechselforschung GmbH 89
Large-scale testing (Phase 3)Study completedNCT01214239
What this trial is testing

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 300
Early research (Phase 1)UnknownNCT06243809
What this trial is testing

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Who this might be right for
Healthy Volunteer
International Bio service 48
Early research (Phase 1)Study completedNCT02183636
What this trial is testing

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Who this might be right for
Healthy
Boehringer Ingelheim 39
Early research (Phase 1)Study completedNCT02223026
What this trial is testing

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

Who this might be right for
Healthy
Boehringer Ingelheim 32
Testing effectiveness (Phase 2)Study completedNCT01342484
What this trial is testing

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 40
Large-scale testing (Phase 3)Study completedNCT00641043
What this trial is testing

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 389
Post-approval studies (Phase 4)Study completedNCT02240680
What this trial is testing

Linagliptin as Add on to Basal Insulin in the Elderly

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 302
Early research (Phase 1)Study completedNCT02183441
What this trial is testing

Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 12
Early research (Phase 1)Study completedNCT05956522
What this trial is testing

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Who this might be right for
Healthy
The Affiliated Hospital of Qingdao University 106
Not applicableEnded earlyNCT01826370
What this trial is testing

Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 678
Early research (Phase 1)Study completedNCT01845077
What this trial is testing

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Who this might be right for
Healthy
Boehringer Ingelheim 72
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation